...
机译:具有Myc和Bcl2的高级B细胞淋巴瘤和/或BCL6与弥漫性大B细胞淋巴瘤形态的重排
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
Mayo Clin Dept Lab Med &
Pathol Rochester MN USA;
Robert Bosch Krankenhaus Dept Clin Pathol Stuttgart Germany;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
Simon Fraser Univ Dept Mol Biol &
Biochem Vancouver BC Canada;
Dr Margarete Fischer Bosch Inst Clin Pharmacol Stuttgart Germany;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
Univ Hosp Muenster Dept Med Hematol &
Oncol Munster Germany;
Saarland Univ Med Sch Dept Internal Med 1 Homburg Germany;
Mayo Clin Dept Oncol Rochester MN USA;
Washington Univ Sch Med St Louis MO USA;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
British Columbia Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;
Robert Bosch Krankenhaus Dept Clin Pathol Stuttgart Germany;
Mayo Clin Dept Lab Med &
Pathol Rochester MN USA;
Wurzburg Univ Inst Pathol Wurzburg Germany;
机译:具有Myc和Bcl2的高级B细胞淋巴瘤和/或BCL6与弥漫性大B细胞淋巴瘤形态的重排
机译:
机译:Burkitt淋巴瘤和其他8个高级B细胞淋巴瘤,具有或不含MYC,BCL2和/或BCL6重排
机译:通过深度学习预测弥漫性大B细胞淋巴瘤标本的MYC易位
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:伴有弥漫性大B细胞淋巴瘤形态的MYC和BCL2和/或BCL6重排的高级B细胞淋巴瘤
机译:高级B细胞淋巴瘤,具有Myc和Bcl2和/或Bcl6重排,弥漫性大B细胞淋巴瘤形态